Thrombin-binding antibody molecules
AssigneeJanssen Pharmaceuticals, Inc.
InventorsJames Andrew Huntington, Trevor Baglin, Jonathan Langdown
Life of this patent
Estimating the term…
Abstract
This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
Claims27
An isolated or recombinant antibody molecule that specifically binds to the exosite 1 region of thrombin, comprising an LCDR1 having the amino acid sequence of SEQ ID NO:
- 15, an LCDR2 having the amino acid sequence of SEQ ID NO:
- 8, and an LCDR3 having the amino acid sequence of SEQ ID NO:
- 9, and comprising an HCDR1 having the amino acid sequence of SEQ ID NO:
- 3, an HCDR2 having the amino acid sequence of SEQ ID NO:
- 4, and an HCDR3 having the amino acid sequence of SEQ ID NO:
- 5.
An isolated or recombinant antibody molecule that specifically binds to the exosite 1 region of thrombin, comprising a variable light chain region (VL) comprising the amino acid sequence of SEQ ID NO:
- 14 and a variable heavy chain region (VH) comprising an HCDR1 having the amino acid sequence of SEQ ID NO:
- 3, an HCDR2 having the amino acid sequence of SEQ ID NO:
- 4, and an HCDR3 having the amino acid sequence of SEQ ID NO:
- 5.
An isolated or recombinant antibody molecule, comprising a variable light chain region (VL) comprising the amino acid sequence of SEQ ID NO:
- 14 and a variable heavy chain region (VH) comprising the amino acid sequence of SEQ ID NO:
- 2.
An isolated or recombinant monoclonal antibody molecule, comprising a variable light chain region (VL) comprising the amino acid sequence of SEQ ID NO:
- 14, a variable heavy chain region (VH) comprising the amino acid sequence of SEQ ID NO:
- 2, and a human IgG constant region.
Dependencies are inferred from the claim text.